Decision-making capacity for research participation among individuals in the CATIE schizophrenia trial

Scott Stroup, Paul Appelbaum, Marvin Swartz, Mukesh Patel, Sonia Davis, Dilip Jeste, Scott Kim, Richard Keefe, Theo Manschreck, Joseph Patrick McEvoy, Jeffrey Lieberman

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Objective: Uncertainty regarding the degree to which persons with schizophrenia may lack decision-making capacity, and what the predictors of capacity may be led us to examine the relationship between psychopathology, neurocognitive functioning, and decision-making capacity in a large sample of persons with schizophrenia at entry into a clinical trial. Method: In the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial, a clinical trial sponsored by the National Institute of Mental Health designed to compare the effectiveness of antipsychotic drugs, subjects were administered the MacArthur Competence Assessment Tool-Clinical Research (MacCAT-CR) and had to demonstrate adequate decision-making capacity before randomization. The MacCAT-CR, the Positive and Negative Syndrome Scale (PANSS), and an extensive neurocognitive battery were completed for 1447 study participants. Results: The neurocognitive composite score and all 5 neurocognitive subscores (verbal memory, vigilance, processing speed, reasoning, and working memory) were positive correlates of the MacCAT-CR understanding, appreciation, and reasoning scales at baseline. Higher levels of negative symptoms, but not positive symptoms, were inversely correlated with these three MacCAT-CR scales. Linear regression models of all three MacCAT-CR scales identified working memory as a predictor; negative symptoms made a small contribution to the understanding and appreciation scores. Conclusions: Negative symptoms and aspects of neurocognitive functioning were correlated with decision-making capacity in this large sample of moderately ill subjects with schizophrenia. In multiple regression models predicting performance on the MacCAT-CR scales, working memory was the only consistent predictor of the components of decision-making capacity. Individuals with schizophrenia who have prominent cognitive dysfunction, especially memory impairment, may warrant particular attention when participating in research.

Original languageEnglish (US)
Pages (from-to)1-8
Number of pages8
JournalSchizophrenia Research
Volume80
Issue number1
DOIs
StatePublished - Dec 1 2005

Fingerprint

Antipsychotic Agents
Schizophrenia
Decision Making
Mental Competency
Clinical Trials
Research
Short-Term Memory
Linear Models
National Institute of Mental Health (U.S.)
Random Allocation
Psychopathology
Uncertainty

Keywords

  • Cross-sectional study
  • Informed consent
  • Mental competency
  • Research subjects
  • Schizophrenia

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Stroup, S., Appelbaum, P., Swartz, M., Patel, M., Davis, S., Jeste, D., ... Lieberman, J. (2005). Decision-making capacity for research participation among individuals in the CATIE schizophrenia trial. Schizophrenia Research, 80(1), 1-8. https://doi.org/10.1016/j.schres.2005.08.007

Decision-making capacity for research participation among individuals in the CATIE schizophrenia trial. / Stroup, Scott; Appelbaum, Paul; Swartz, Marvin; Patel, Mukesh; Davis, Sonia; Jeste, Dilip; Kim, Scott; Keefe, Richard; Manschreck, Theo; McEvoy, Joseph Patrick; Lieberman, Jeffrey.

In: Schizophrenia Research, Vol. 80, No. 1, 01.12.2005, p. 1-8.

Research output: Contribution to journalArticle

Stroup, S, Appelbaum, P, Swartz, M, Patel, M, Davis, S, Jeste, D, Kim, S, Keefe, R, Manschreck, T, McEvoy, JP & Lieberman, J 2005, 'Decision-making capacity for research participation among individuals in the CATIE schizophrenia trial', Schizophrenia Research, vol. 80, no. 1, pp. 1-8. https://doi.org/10.1016/j.schres.2005.08.007
Stroup, Scott ; Appelbaum, Paul ; Swartz, Marvin ; Patel, Mukesh ; Davis, Sonia ; Jeste, Dilip ; Kim, Scott ; Keefe, Richard ; Manschreck, Theo ; McEvoy, Joseph Patrick ; Lieberman, Jeffrey. / Decision-making capacity for research participation among individuals in the CATIE schizophrenia trial. In: Schizophrenia Research. 2005 ; Vol. 80, No. 1. pp. 1-8.
@article{ac2d456d88494aa8b69789049383c4b0,
title = "Decision-making capacity for research participation among individuals in the CATIE schizophrenia trial",
abstract = "Objective: Uncertainty regarding the degree to which persons with schizophrenia may lack decision-making capacity, and what the predictors of capacity may be led us to examine the relationship between psychopathology, neurocognitive functioning, and decision-making capacity in a large sample of persons with schizophrenia at entry into a clinical trial. Method: In the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial, a clinical trial sponsored by the National Institute of Mental Health designed to compare the effectiveness of antipsychotic drugs, subjects were administered the MacArthur Competence Assessment Tool-Clinical Research (MacCAT-CR) and had to demonstrate adequate decision-making capacity before randomization. The MacCAT-CR, the Positive and Negative Syndrome Scale (PANSS), and an extensive neurocognitive battery were completed for 1447 study participants. Results: The neurocognitive composite score and all 5 neurocognitive subscores (verbal memory, vigilance, processing speed, reasoning, and working memory) were positive correlates of the MacCAT-CR understanding, appreciation, and reasoning scales at baseline. Higher levels of negative symptoms, but not positive symptoms, were inversely correlated with these three MacCAT-CR scales. Linear regression models of all three MacCAT-CR scales identified working memory as a predictor; negative symptoms made a small contribution to the understanding and appreciation scores. Conclusions: Negative symptoms and aspects of neurocognitive functioning were correlated with decision-making capacity in this large sample of moderately ill subjects with schizophrenia. In multiple regression models predicting performance on the MacCAT-CR scales, working memory was the only consistent predictor of the components of decision-making capacity. Individuals with schizophrenia who have prominent cognitive dysfunction, especially memory impairment, may warrant particular attention when participating in research.",
keywords = "Cross-sectional study, Informed consent, Mental competency, Research subjects, Schizophrenia",
author = "Scott Stroup and Paul Appelbaum and Marvin Swartz and Mukesh Patel and Sonia Davis and Dilip Jeste and Scott Kim and Richard Keefe and Theo Manschreck and McEvoy, {Joseph Patrick} and Jeffrey Lieberman",
year = "2005",
month = "12",
day = "1",
doi = "10.1016/j.schres.2005.08.007",
language = "English (US)",
volume = "80",
pages = "1--8",
journal = "Schizophrenia Research",
issn = "0920-9964",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Decision-making capacity for research participation among individuals in the CATIE schizophrenia trial

AU - Stroup, Scott

AU - Appelbaum, Paul

AU - Swartz, Marvin

AU - Patel, Mukesh

AU - Davis, Sonia

AU - Jeste, Dilip

AU - Kim, Scott

AU - Keefe, Richard

AU - Manschreck, Theo

AU - McEvoy, Joseph Patrick

AU - Lieberman, Jeffrey

PY - 2005/12/1

Y1 - 2005/12/1

N2 - Objective: Uncertainty regarding the degree to which persons with schizophrenia may lack decision-making capacity, and what the predictors of capacity may be led us to examine the relationship between psychopathology, neurocognitive functioning, and decision-making capacity in a large sample of persons with schizophrenia at entry into a clinical trial. Method: In the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial, a clinical trial sponsored by the National Institute of Mental Health designed to compare the effectiveness of antipsychotic drugs, subjects were administered the MacArthur Competence Assessment Tool-Clinical Research (MacCAT-CR) and had to demonstrate adequate decision-making capacity before randomization. The MacCAT-CR, the Positive and Negative Syndrome Scale (PANSS), and an extensive neurocognitive battery were completed for 1447 study participants. Results: The neurocognitive composite score and all 5 neurocognitive subscores (verbal memory, vigilance, processing speed, reasoning, and working memory) were positive correlates of the MacCAT-CR understanding, appreciation, and reasoning scales at baseline. Higher levels of negative symptoms, but not positive symptoms, were inversely correlated with these three MacCAT-CR scales. Linear regression models of all three MacCAT-CR scales identified working memory as a predictor; negative symptoms made a small contribution to the understanding and appreciation scores. Conclusions: Negative symptoms and aspects of neurocognitive functioning were correlated with decision-making capacity in this large sample of moderately ill subjects with schizophrenia. In multiple regression models predicting performance on the MacCAT-CR scales, working memory was the only consistent predictor of the components of decision-making capacity. Individuals with schizophrenia who have prominent cognitive dysfunction, especially memory impairment, may warrant particular attention when participating in research.

AB - Objective: Uncertainty regarding the degree to which persons with schizophrenia may lack decision-making capacity, and what the predictors of capacity may be led us to examine the relationship between psychopathology, neurocognitive functioning, and decision-making capacity in a large sample of persons with schizophrenia at entry into a clinical trial. Method: In the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial, a clinical trial sponsored by the National Institute of Mental Health designed to compare the effectiveness of antipsychotic drugs, subjects were administered the MacArthur Competence Assessment Tool-Clinical Research (MacCAT-CR) and had to demonstrate adequate decision-making capacity before randomization. The MacCAT-CR, the Positive and Negative Syndrome Scale (PANSS), and an extensive neurocognitive battery were completed for 1447 study participants. Results: The neurocognitive composite score and all 5 neurocognitive subscores (verbal memory, vigilance, processing speed, reasoning, and working memory) were positive correlates of the MacCAT-CR understanding, appreciation, and reasoning scales at baseline. Higher levels of negative symptoms, but not positive symptoms, were inversely correlated with these three MacCAT-CR scales. Linear regression models of all three MacCAT-CR scales identified working memory as a predictor; negative symptoms made a small contribution to the understanding and appreciation scores. Conclusions: Negative symptoms and aspects of neurocognitive functioning were correlated with decision-making capacity in this large sample of moderately ill subjects with schizophrenia. In multiple regression models predicting performance on the MacCAT-CR scales, working memory was the only consistent predictor of the components of decision-making capacity. Individuals with schizophrenia who have prominent cognitive dysfunction, especially memory impairment, may warrant particular attention when participating in research.

KW - Cross-sectional study

KW - Informed consent

KW - Mental competency

KW - Research subjects

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=27744497490&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27744497490&partnerID=8YFLogxK

U2 - 10.1016/j.schres.2005.08.007

DO - 10.1016/j.schres.2005.08.007

M3 - Article

C2 - 16182516

AN - SCOPUS:27744497490

VL - 80

SP - 1

EP - 8

JO - Schizophrenia Research

JF - Schizophrenia Research

SN - 0920-9964

IS - 1

ER -